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CD54/intercellular adhesion molecule-1 (ICAM-1) is generallly found
at lower levels in B-cell chronic lymphocytic leukemia (B-CLL) and its
higher expression has been already associated with marked
organomegaly and poor prognosis (Hjalmar, 2002). Furthermore, it has
been clearly demonstrated that ZAP-70+ CLL shows a rapid disease pro-
gression and an inferior overall survival (Crespo, 2003; Del Principe,
2006). The primary aims of our research were: 1) to correlate CD54 with
other recent biologic prognostic factors, 2) to determine progression-
free survival (PFS) upon CD54 expression; 3) whether CD54 could pre-
dict varied outcome within ZAP-70+ and ZAP-70 negative subgroups;
and finally, 4) to test the independent value of CD54 as prognosticator.
Therefore, we investigated 202 pts, median age 65 years (range 37-87),
105 males and 97 females. With regard to modified Rai stages, 64 pts had
a low stage, 132 an intermediate stage and 6 a high stage. CD54 was
determined by multicolor flow cytometry fixing a cut-off value of 30%.
CD54+ B-CLL pts were 131/202 (65%). CD54>30% was associated with
an intermediate/high Rai stage (p=0.008), with marked lymphadenopa-
thy and/or splenomegaly (p=0.00001) and with beta-2 microglobulin
>2.2 mg/dL (p=0.0006). Also, high CD54 and IgVH unmutated status
(<2%) were correlated (25/29; p=0.001). Furthermore, significant asso-
ciations were found either between higher CD54 and higher ZAP-70
(59/79; p=0.01) or between higher CD54 and higher soluble CD23
(sCD23) levels (48/59; p=0.002). A significant shorter PFS was observed
in CD54+ pts (22% vs. 72% at 14 years; p<0.00001, Figure 1) as well as
in ZAP-70+ pts (15% vs. 63% at 10 years; p<0.00001). To further explore
the prognostic impact of CD54, we investigated its expression within
ZAP-70+ (79 pts) and ZAP-70 negative (123 pts) subsets. As a matter of
fact, CD54+ pts showed a shorter PFS both within the ZAP-70+ subset
(13% vs. 22% at 10 years; p=0.03) and within the ZAP-70 negative sub-
set (42% vs. 91% at 14 years, p=0.0001). In multivariate analysis of PFS
both ZAP-70 (p=0.0001) and CD54 (p=0.004) resulted to be independ-
ent prognostic factors. Therefore, CD54, determined by flow cytome-
try, could be considered as a promising prognostic parameter in B-CLL.
Moreover, since the ZAP-70 negative subgroup consists of a large and a
heterogeneous population presenting variable outcome, CD54 should be
used to identify B-CLL progressive pts, particularly those with important
organomegaly.
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Distinct genetic abnormalities such as TP53 deletion at 17p13.1 have
been identified as having adverse prognostic relevance in B-cell chronic
lymphocytic leukemia (B-CLL), and conventional cytogenetic studies
have shown that TP53 deletion in B-CLL is mainly associated with the
loss of 17p due to complex chromosomal rearrangements. We used an
integrative genomic approach to investigate the significance of 17p loss
in a subset of B-CLLs carrying a TP53 monoallelic deletion detected by
Fluorescence in-situ hybridization (FISH). A panel of 71 untreated Binet
A B-CLLs (18 carrying 17p-) was characterized for the most recurrent
genomic aberrations and for the major prognostic markers. The genom-
ic profile of chromosome 17p was investigated with GeneChip Human
Mapping 50K Xba arrays in 12/18 17p- B-CLLs. Inferred copy numbers
were derived from a Hidden Markov Model (HMM) based algorithm
implemented in CNAT 4.0.1 software (Affymetrix). FISH probes cover-
ing a region of approximately 6 Mb in 17p11.2-p12 was selected to val-
idate the array results. The transcriptional profiles of the 60 B-CLLs (7
carrying 17p-) have been generated on Affymetrix GeneChip U133A
arrays. The identified transcriptional fingerprints of the 17p- cases was
validated on an independent dataset of 100 B-CLL cases (Haslinger et al.,
2004) using a Multi-class Prediction Analysis. Polymerase chain reaction
was used to define the mutational status of the TP53. Genome-wide
DNA analysis of TP53-deleted samples showed 17p loss in 11/12 cases,
with breakpoints scattered along the 17p11.2 region. FISH analysis con-
firmed these findings and revealed 17p loss in a small fraction of
leukemic cells in the remaining TP53-deleted case. In addition, FISH indi-
cated 17p loss in the 6/18 cases not investigated by SNP. Mutations in
exons 2 to 11 of the remaining TP53 allele were found in 9/12 17p- B-
CLLs. Gene expression profiling of 60 B-CLLs, identified 40 differential-
ly expressed genes in 17p- versus 17p normal samples, 35 of which were
down-regulated in 17p- tumors: the majority (30/35) of these transcripts,
including putative tumor suppressor genes (GABARAP, GPS2 and
OVCA1) mapped to 17p, indicating a remarkable gene dosage effect.
Our data provide evidence that 17p loss may play an additional patho-
genetic role in B-CLL, and suggest that the concomitant loss of multiple
tumor suppressor genes could be responsible for the highly adverse prog-
nostic relevance associated with TP53 loss.
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B-cell chronic lymphocytic leukemia (B-CLL) is a clonal lymphopro-
liferative disease characterized by the expansion of mature CD5+ B-
cells. Recent studies indicated that variability in clinical outcomes
observed in CLL patients is related to differences in the ability to trans-
duce B-cell receptor (BCR)-mediate signals. The BCR signal transduction
routes include, in the initial phases, Syk tyrosin kinase and BCR pro-
longed stimulation has been associated to activation of kinases includ-
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